Unit Head: Annalise Di Marco [Ph. D.]

Hit expansion, lead finding and lead optimization require strong expertise and capabilities in developing, deploying and analyzing pharmacological assays. Our in vitro pharmacology group provides this know-how through a decades-long experience in the field, coupled with sensitive and highly validated in vitro assays and models to evaluate your compounds’ pharmacology and inform subsequent decision.

IRBMOur team can provide potency and selectivity testing for small molecules and biologics, alongside with support on the investigation of receptor or protein biochemistry. Gold-standard industry assays such as CYP450 inhibition, hERG channel binding, and CYP induction are readily available, coupled with proprietary assays such as our in vitro blood-brain barrier permeability assay, designed to mitigate risks to your project in downstream phases of development.

In addition, our team has significant expertise in cell biology, including the isolation and cultivation of primary cells from a variety of sources (e.g. neurons, astrocytes, hepatocytes, PBMC, fibroblasts, etc.), including both 2D and 3D culture, and can provide relevant cellular models to further characterize the pharmacology of your hit compounds and their derivatives. Through our in vitro expertise and state-of-the-art technology, our team can provide a full range of ADME services, including, but not limited to, cytotoxicity, drug-drug interaction potentials, off-target activities, metabolic stability and drug disposition of your lead compound, as well.

For use in experimental study and disease-modelling, a stem-cells based infrastructure is under development.

With a strong track record in multiple different therapeutic areas, such as metabolic diseases, neurodegeneration, cardiovascular diseases, infectious diseases and oncology, our team can provide your project with a complete ADME package, supporting the selection of the most appropriate compounds for the Preclinical Research phase, as well as providing predictions on human in vivo properties..

In addition to its support role in integrated projects, our In Vitro Pharmacology team stands ready to assist with smaller-scale ADME projects as well.

Unit Capabilities

  • ADME;
  • Cytotoxicity assays;
  • Drug-drug interaction studies;
  • Off-target activities;
  • Metabolic stability and drug disposition;
  • In vitro cell biology models;
  • Highly sensitive in vitro assays (CYP450 inhibition, hERG channel binding, CYP induction, etc.);
  • Robust potency and selectivity testing;
  • Blood-brain barrier penetration expertise and proprietary in vitro model, predictive of in vivo properties.